Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.

Clark BA, Sessink PJ.

J Oncol Pharm Pract. 2013 Jun;19(2):99-104. doi: 10.1177/1078155212468367. Epub 2013 Jan 4.

PMID:
23292973
2.
3.

Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.

Siderov J, Kirsa S, McLauchlan R.

J Oncol Pharm Pract. 2010 Mar;16(1):19-25. doi: 10.1177/1078155209352543. Epub 2009 Dec 4.

PMID:
19965949
4.

Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Sessink PJ, Connor TH, Jorgenson JA, Tyler TG.

J Oncol Pharm Pract. 2011 Mar;17(1):39-48. doi: 10.1177/1078155210361431. Epub 2010 Feb 15.

5.

Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.

Wick C, Slawson MH, Jorgenson JA, Tyler LS.

Am J Health Syst Pharm. 2003 Nov 15;60(22):2314-20.

PMID:
14652980
6.

Evaluation of surface contamination with cyclophosphamide following simulated hazardous drug preparation activities using two closed-system products.

Zock MD, Soefje S, Rickabaugh K.

J Oncol Pharm Pract. 2011 Mar;17(1):49-54. doi: 10.1177/1078155210374673. Epub 2010 Jun 28.

7.

Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.

Guillemette A, Langlois H, Voisine M, Merger D, Therrien R, Mercier G, Lebel D, Bussières JF.

J Oncol Pharm Pract. 2014 Dec;20(6):426-32. doi: 10.1177/1078155213517127. Epub 2014 Jan 6.

PMID:
24395542
8.

Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators.

Forges F, Simoens X, Chauvin F.

J Oncol Pharm Pract. 2011 Mar;17(1):61-7. doi: 10.1177/1078155210380291. Epub 2010 Aug 10.

PMID:
20699332
9.

Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation.

Sessink PJ, Leclercq GM, Wouters DM, Halbardier L, Hammad C, Kassoul N.

J Oncol Pharm Pract. 2015 Apr;21(2):118-27. doi: 10.1177/1078155214522840. Epub 2014 Feb 23.

PMID:
24567041
10.

Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.

Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA.

Am J Health Syst Pharm. 1999 Jul 15;56(14):1427-32.

PMID:
10428450
11.

Syringe plunger contamination by hazardous drugs: a comparative study.

Smith ST, Szlaczky MC.

J Oncol Pharm Pract. 2014 Oct;20(5):381-5. doi: 10.1177/1078155214526428. Epub 2014 Mar 5.

PMID:
24598373
12.

A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination.

Bobin-Dubigeon C, Amiand M, Percheron C, Audeval C, Rochard S, Leynia P, Bard JM.

J Anal Toxicol. 2013 Sep;37(7):433-9. doi: 10.1093/jat/bkt045. Epub 2013 Jul 4.

PMID:
23828102
13.

Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department.

Castiglia L, Miraglia N, Pieri M, Simonelli A, Basilicata P, Genovese G, Guadagni R, Acampora A, Sannolo N, Scafarto MV.

J Occup Health. 2008;50(1):48-56.

14.

Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.

Chu WC, Hon CY, Danyluk Q, Chua PP, Astrakianakis G.

J Oncol Pharm Pract. 2012 Mar;18(1):46-51. doi: 10.1177/1078155211402106. Epub 2011 Jul 7.

PMID:
21737485
15.

Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.

Yoshida J, Tei G, Mochizuki C, Masu Y, Koda S, Kumagai S.

Ann Occup Hyg. 2009 Mar;53(2):153-60. doi: 10.1093/annhyg/men081.

PMID:
19261696
16.

Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator.

Vyas N, Turner A, Clark JM, Sewell GJ.

J Oncol Pharm Pract. 2016 Feb;22(1):10-9. doi: 10.1177/1078155214544993. Epub 2014 Jul 29.

PMID:
25073678
17.

Development of a closed drug preparation method for oral anticancer drugs.

Wakui N, Ookubo T, Iwasaki Y, Ito R, Saito K, Nakazawa H.

J Oncol Pharm Pract. 2013 Dec;19(4):315-20. doi: 10.1177/1078155212467554. Epub 2013 Jan 4.

PMID:
23292970
18.

[Determination of airborne and surface contamination with cyclophosphamide at the Masaryk Memorial Cancer Institute, Brno, Czech Republic].

Gorná L, Odráska P, Dolezalová L, Piler P, Oravec M, Bláha L.

Ceska Slov Farm. 2011 Feb;60(1):25-31. Czech.

PMID:
21650015
19.

[Field survey of the anticancer drug contamination in the preparation environment. Usefulness of the 5-FU monitoring by the coupon method].

Sato J, Mori M, Sasaki T, Nihei S, Kumagai M, Nakayama S, Takahashi K, Kudo K.

Yakugaku Zasshi. 2014;134(6):751-6. Japanese.

20.

A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals.

Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F, Sannolo N.

Ann Occup Hyg. 2005 Oct;49(7):611-8. Epub 2005 Jun 17.

PMID:
15964876

Supplemental Content

Support Center